ENDRA Life Sciences NDRA recently announced positive findings from a clinical study assessing the measurement consistency of ...

WASHINGTON & OXFORD, England--(BUSINESS WIRE)--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated steatohepatitis ...

ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the ...

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ANN ARBOR, ...

Adding MRI to CT may improve the accuracy of detecting nonviable disappearing liver metastases than CT alone among patients with initially unresectable colorectal liver metastases. However, confirmed ...

This prospective study included 135 patients (median age, 67 years; 66 women) who underwent MRI-guided SBRT for liver metastases across seven international centres between April 2019 and April 2023.

The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. Risk of peritoneal recurrence ...

Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc ...

Non-alcoholic fatty liver disease (NAFLD) is increasing in prevalence worldwide. NAFLD is associated with excess risk of all-cause mortality, and its progression to non-alcoholic steatohepatitis (NASH ...